Claus models breast cancer in terms of a single, rare, highly penetrant gene.The extended version of the Claus model (eCLAUS) as implemented in Cyrillic 2.12 moreover includes ovarian cancer occurrence in families.
Methods & Phenotypes
GC-HBOC-MFE characterises the mutation prevalences in different family constellations with breast and ovarian cancers (BCOC) for different BCOC related genes (e.g. BRCA1, BRCA2, CHEK2, RAD51C,...) . Data stem from about 40.000 families that were gathered since 1996 in a clinical setting by the GC-HBOC, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and the mutation status of the index patient.
The toxcalculator is a web-based tool to calculate prognostic scores on haematopoietic toxicity for 6 cycles CHOP-like regimen in patients with aggressive NHL.
Preprocessing Illumina HT12v4 gene expression data including quality filtering, data transformation and normalisation and batch-effect removal as well as visualisation
The Manchester scoring system is a tool to predict mutations risks for BRCA1/2 in families with multiple and/or early-onset cases of breast and ovarian cancers.
MMRpredict is a risk prediction model for patients with colorectal cancer only (Barnetson et al. 2006). It calculates the risk for having a mutation in MLH1, MSH2 and MSH6 (combined) based on the history of colorectal and endometrium cancers in the family (stage 1).
This is an interactive version of figure 4 of the publication „Integration of Genome-Wide SNP Data and Gene-Expression Profiles Reveals Six Novel Loci and Regulatory Mechanisms for Amino Acids and Acylcarnitines in Whole Blood“.
Das NLP4CR-Tool ist ein Prototyp, der die Anwendbarkeit von Apache UIMA und cTakes auf medizinische Volltexte in deutscher Sprache zeigt.
Analysis of large-scale molecular biological data using self-organizing maps
The PREMM1,2,6 estimates the risk of having a mutation in MLH1, MSH2 and MSH6 based on the cancer history of the index patient and its family for families with Lynch-related cancers.